International Collaborative Gaucher Group (ICGG) Gaucher Registry
Status: | Recruiting |
---|---|
Conditions: | Neurology, Endocrine, Metabolic |
Therapuetic Areas: | Endocrinology, Neurology, Pharmacology / Toxicology |
Healthy: | No |
Age Range: | Any |
Updated: | 3/15/2019 |
Start Date: | April 1991 |
End Date: | January 31, 2030 |
Contact: | For site information, send an email with site number to |
Email: | Contact-Us@sanofi.com |
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational
program that tracks the routine clinical outcomes for patients with Gaucher disease,
irrespective of treatment status. No experimental intervention is involved; patients in the
Registry undergo clinical assessments and receive care as determined by the patient's
treating physician.
The objectives of the Registry are:
- To enhance the understanding of the variability, progression, and natural history of
Gaucher disease with the ultimate goal of better guiding and assessing therapeutic
interventions;
- To provide the Gaucher medical community with recommendations for monitoring patients
and to provide reports on patient outcomes to help optimize patient care; and
- To evaluate the long-term effectiveness of Cerezyme.
program that tracks the routine clinical outcomes for patients with Gaucher disease,
irrespective of treatment status. No experimental intervention is involved; patients in the
Registry undergo clinical assessments and receive care as determined by the patient's
treating physician.
The objectives of the Registry are:
- To enhance the understanding of the variability, progression, and natural history of
Gaucher disease with the ultimate goal of better guiding and assessing therapeutic
interventions;
- To provide the Gaucher medical community with recommendations for monitoring patients
and to provide reports on patient outcomes to help optimize patient care; and
- To evaluate the long-term effectiveness of Cerezyme.
Inclusion Criteria:
- All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion
in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase
deficiency and/or mutation in the β-glucocerebrosidase gene.
- For all patients, appropriate patient authorization will be obtained.
Exclusion Criteria:
- No exclusion criteria for participation in the ICGG Gaucher Registry.NOTE: Registry
participation does not exclude participation in other clinical studies.
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials